AIMS: To investigate whether plasma levels of endothelin-1 (ET-1), a potent vasoconstricting peptide that is crucial in regulating retinal blood flow, were elevated in patients with retinal vein occlusion (RVO). METHODS:ET-1plasma concentrations were determined by radioimmunoassays in a double blind fashion in a group of 18 selected patients with RVO, in 20 healthy age matched non-smoking, normoglycaemic, normotensive control subjects, and in 15 patients with uncomplicated essential hypertension in the same age range. RESULTS:Patients with RVO had significantly increased ET-1 plasma levels (14.22 (SD 4.6) pg/ml) compared with both normal subjects (7.90 (1.6) pg/ml; p < 0.05) and hypertensive patients (8.50 (2.9) pg/ml; p < 0.05). The highest concentrations of circulating ET-1 were found in patients with RVO of the ischaemic type (16.97 (3.5) pg/ml; p < 0.01; n = 7). Systemic hypertension alone did not account for the observed increase in plasmaET-1 concentrations. CONCLUSIONS: These findings raise the possibility that the increased circulating ET-1 levels in patients with RVO may be a marker of the occlusive event, thereby suggesting that ET-1 homeostasis may be relevant to RVO pathogenesis and retinal ischaemic manifestations.
RCT Entities:
AIMS: To investigate whether plasma levels of endothelin-1 (ET-1), a potent vasoconstricting peptide that is crucial in regulating retinal blood flow, were elevated in patients with retinal vein occlusion (RVO). METHODS:ET-1 plasma concentrations were determined by radioimmunoassays in a double blind fashion in a group of 18 selected patients with RVO, in 20 healthy age matched non-smoking, normoglycaemic, normotensive control subjects, and in 15 patients with uncomplicated essential hypertension in the same age range. RESULTS:Patients with RVO had significantly increased ET-1 plasma levels (14.22 (SD 4.6) pg/ml) compared with both normal subjects (7.90 (1.6) pg/ml; p < 0.05) and hypertensivepatients (8.50 (2.9) pg/ml; p < 0.05). The highest concentrations of circulating ET-1 were found in patients with RVO of the ischaemic type (16.97 (3.5) pg/ml; p < 0.01; n = 7). Systemic hypertension alone did not account for the observed increase in plasma ET-1 concentrations. CONCLUSIONS: These findings raise the possibility that the increased circulating ET-1 levels in patients with RVO may be a marker of the occlusive event, thereby suggesting that ET-1 homeostasis may be relevant to RVO pathogenesis and retinal ischaemic manifestations.
Authors: C Letizia; A Iannaccone; S Cerci; G Santi; M Cilli; S Coassin; M R Pannarale; D Scavo; A Iannacone Journal: Horm Metab Res Date: 1997-05 Impact factor: 2.936
Authors: L E Smith; J J Kopchick; W Chen; J Knapp; F Kinose; D Daley; E Foley; R G Smith; J M Schaeffer Journal: Science Date: 1997-06-13 Impact factor: 47.728
Authors: C Takagi; S E Bursell; Y W Lin; H Takagi; E Duh; Z Jiang; A C Clermont; G L King Journal: Invest Ophthalmol Vis Sci Date: 1996-11 Impact factor: 4.799
Authors: K Metsärinne; D Nordström; S Santavirta; A Kauste; I Tikkanen; F Fyhrquist Journal: Scand J Clin Lab Invest Date: 1995-05 Impact factor: 1.713
Authors: Luke B Potts; Yi Ren; Guangrong Lu; Enoch Kuo; Ellen Ngo; Lih Kuo; Travis W Hein Journal: Invest Ophthalmol Vis Sci Date: 2012-05-17 Impact factor: 4.799
Authors: Travis W Hein; Robert H Rosa; Zhaoxu Yuan; Elizabeth Roberts; Lih Kuo Journal: Invest Ophthalmol Vis Sci Date: 2009-10-22 Impact factor: 4.799